Overview of Korean Botox Brands

By Your Health Magazine Contributor

Your Health Magazine Contributor

. https://YourHealthMagazine.net

More Beauty Skin Care & Gorgeous Smiles Articles

Overview of Korean Botox Brands

South Korea now hosts more than a dozen manufacturers of botulinum toxin type A, and two Korean products carry full U.S. FDA approval. Korean botox brands have moved well past novelty status. This guide breaks down the formulations, clinical data, and regulatory milestones of the leading brands available in 2026.

Key Takeaways

• “Korean botox” means botulinum toxin type A made in South Korea by companies like Daewoong Pharmaceutical (Nabota), Hugel (Botulax/Letybo), Medytox (Innotox/Neuronox), and Huons (Liztox).
• Innotox is the first pre-mixed liquid formulation, removing on-site reconstitution and reducing dilution errors. Additional information about Innotox for sale at Filler Supplies is intended for licensed healthcare professionals.
• Clinical trials show Korean toxins perform comparably to Allergan Botox for glabellar lines, crow’s feet, and forehead wrinkles, with differences mainly in price, onset, and diffusion.
• Two brands hold U.S. FDA approval: Nabota (as Jeuveau, Feb 2019) and Botulax (as Letybo, Feb 2024).
• Injector expertise, correct dilution, verified cold-chain sourcing, and patient-specific dosing matter more than the brand on the vial.

What Is Korean Botox?

Korean botox is purified botulinum toxin type A, derived from Clostridium botulinum — the same neurotoxin used in Allergan’s Botox. It temporarily relaxes targeted muscles by blocking acetylcholine at the neuromuscular junction, softening the dynamic wrinkles caused by repeated expressions.

Common targets include frown lines, crow’s feet, forehead lines, and the masseter muscles for jaw contouring. Beyond aesthetics, these toxins also treat conditions such as spasticity, muscle spasms, and hyperhidrosis. All are regulated by Korea’s MFDS as prescription biologics; some also hold CE marking or FDA approval for specific indications.

How Korean Toxins Compare to Western Brands

All botulinum toxin type A products — Korean or Western (Allergan Botox, Dysport, Xeomin) — share the same core mechanism. The differences are in formulation and regulatory history.

• Purity and complexing proteins. Allergan Botox uses a ~900 kDa complex with accessory proteins. Some Korean products (Coretox, Innotox) strip these away, leaving only the 150 kDa “naked” neurotoxin.
• Onset and duration. Nabota shows effects within 2–4 days, comparable to Allergan Botox. Duration for both typically runs 3–6 months, depending on dose and treatment area.
• Protein load and immunogenicity. A potency study found letibotulinumtoxinA (Botulax) contained ~118.9% of the neurotoxin protein per 100 U vial versus onabotulinumtoxinA at 100%. Higher protein content raises theoretical concerns about antibody resistance over repeated treatments.
• Cost. Korean brands are usually more affordable per unit, letting clinics treat larger areas at lower total cost.

Nabota (Jeuveau)

Manufactured by Daewoong Pharmaceutical and sold in the U.S. as Jeuveau, Nabota is the most internationally recognized Korean brand. Its HI-PURE process yields a ~900 kDa complex structurally comparable to Allergan Botox, supplied in 100 U lyophilized vials.

It received U.S. FDA approval for moderate-to-severe glabellar lines in February 2019, and also holds approvals in Korea, Canada, parts of Europe, and Latin America. A phase IV study (42 subjects) found 85.4% showed glabellar improvement at maximum frown by day 2 after a 20 U injection, with peak effect around 7–10 days. A separate phase III RCT (197 post-stroke patients) showed non-inferiority to Allergan Botox for upper-limb spasticity. Side effects (headache, eyelid drooping) match the class-wide profile.

Botulax (Letybo)

Made by Hugel, Botulax is a botulinum toxin type A complex supplied as lyophilized powder in 50 U, 100 U, and 200 U vials, stabilized with human serum albumin and sucrose. Its predictable diffusion suits both broad and delicate work when handled by experienced injectors.

Hugel obtained U.S. FDA approval in February 2024 under the name Letybo, giving it dual U.S./EU access alongside MFDS authorization. Because Botulax carries more neurotoxin protein per unit than onabotulinumtoxinA, 1:1 unit conversion should not be assumed. Clinics favor it for its balance of cost, consistency, and flexible vial sizes.

Innotox

Made by Medytox and MFDS-approved for glabellar lines (20 U) in 2013, Innotox is the only major Korean toxin that ships as a ready-to-use liquid, eliminating the reconstitution step. Its active core is a 150 kDa neurotoxin with minimal complexing proteins; it contains no human serum albumin, using polysorbate and methionine as stabilizers. It comes in 25 U and 50 U vials stored at 2–8 °C.

The pre-mixed format reduces dilution errors and contamination risk and improves dosing consistency between sessions — useful for high-volume clinics. Its smooth diffusion suits fine upper-face work (periorbital, forehead, bunny lines) and subtle, natural-looking results.

Other Notable Brands

Liztox (Huons) reaches ~99.8% purity, lowering immunogenic risk for long-term patients. A phase III RCT across six Seoul hospitals showed non-inferiority to Allergan Botox for post-stroke wrist-flexor spasticity, sustained through week 12. MFDS-approved for glabellar lines.

Neuronox / Meditoxin (Medytox) is one of the earlier Korean toxins, used across Asia for over a decade, broadly comparable to onabotulinumtoxinA in published studies.

Coretox (Medytox) is a “naked” 150 kDa neurotoxin without complexing proteins, positioned to minimize immunogenicity. Others — Rentox, Wondertox, Toxta, Metox — are niche options with limited peer-reviewed data outside domestic markets.

Because unit potency varies between products, clinicians should never assume 1:1 equivalence without brand-specific training.

Efficacy, Safety, and Side Effects

Korean toxins have been tested in multiple randomized trials, frequently showing non-inferiority to Allergan Botox for standard cosmetic indications.

• Typical outcomes: visible improvement in 2–7 days, peak at 1–2 weeks, average duration 3–6 months. Masseter, hyperhidrosis, and higher-dose protocols can last 6–9 months.
• Common side effects: transient redness, swelling, bruising, mild headache, and temporary weakness in adjacent muscles if the toxin diffuses beyond the target zone. Most resolve within days.
• Rare risks: ptosis, asymmetry, and dysphagia — correlating more with technique and dosing than with any specific brand.
• Immunogenicity: formulations with minimal or no complexing proteins (Coretox, Innotox, Liztox) are designed to reduce neutralizing-antibody risk. An Asia-Pacific physician survey confirmed antibody-mediated failure is rare but rises with short intervals and high cumulative doses.

Korean vs American Botox

The choice comes down to budget, regulatory access, and aesthetic priorities — not a fundamental safety gap, assuming both products are authentic and properly stored. Korean brands are usually cheaper per unit; Allergan Botox has the broadest global footprint and a 20-plus-year track record. In the U.S., only Jeuveau and Letybo hold FDA approval as of mid-2026. Brand should be chosen in consultation, matched to the patient’s anatomy, muscle strength, and prior response — never by marketing alone.

Safe Sourcing and Handling

Storage failures, counterfeit vials, and unqualified injectors cause far more adverse events than any difference between reputable brands.

• Store lyophilized and liquid products at 2–8 °C, protected from light, and reconstitute (where needed) with preservative-free saline per manufacturer instructions.
• Units are not interchangeable between brands; follow official conversion tables and start conservatively when switching.
• Healthcare professionals should obtain products through authorized distribution channels with documented cold-chain handling and batch traceability. The FDA’s April 2026 warning letter to Beauty Aztlan LLC for selling unapproved Botulax and Innotox underscores the risk of unverified channels.
• Patients should never buy or self-inject toxin — these are prescription-only medicines requiring trained oversight.

FAQ

Is Korean botox as safe as Allergan Botox? MFDS-approved brands with published trials (Nabota, Botulax, Innotox, Liztox, Letybo, Neuronox) have comparable safety profiles when used correctly. Differences in outcomes almost always trace to counterfeit product, poor storage, or unqualified injectors — not to country of origin.

How long do the effects last? About 3–6 months for standard cosmetic areas, similar to American Botox. Masseter, hyperhidrosis, and higher-dose protocols can last 6–9 months.

Can I mix different brands in one plan? Different brands across separate sessions or areas is common, but mixing within one syringe or field is discouraged without a clear protocol, since unit equivalence isn’t guaranteed.

How does Innotox differ from lyophilized formulations? The pre-mixed format removes dilution steps and handling errors, but it doesn’t change the pharmacology. Whether it’s “better” depends on the indication and injector preference. Innotox is intended for use by licensed healthcare professionals where permitted by local regulations.

How do I know my clinic uses genuine product? Ask which brand they use and request to see the sealed vial — check packaging, lot number, and expiry. If a clinic can’t name the brand or show the vial, treat that as a red flag.